Guta Mistire Teshome, Tekalign Tiwabwork, Awoke Nefsu, Fite Robera Olana, Dendir Getahun, Lenjebo Tsegaye Lolaso
School of Nursing, College of Health Science and Medicine, Wolaita Sodo University, Wolaita Sodo, Ethiopia.
HaSET Program/Ethiopian Public Health Institute, Adis Abeba, Ethiopia.
Int J Chronic Dis. 2021 Jul 7;2021:6708865. doi: 10.1155/2021/6708865. eCollection 2021.
This systemic review and meta-analysis were aimed at determining the level of anxiety and depression among cystic fibrosis patients in the world.
We conducted a systematic search of published studies from PubMed, EMBASE, MEDLINE, Cochrane, Scopus, Web of Science, CINAHL, and manually on Google Scholar. This meta-analysis follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The quality of studies was assessed by the modified Newcastle-Ottawa Scale (NOS). Meta-analysis was carried out using a random-effects method using the STATA™ Version 14 software. Trim and fill analysis was done to correct the presence of significant publication bias.
From 419,820 obtained studies, 26 studies from 2 different parts of the world including 9766. The overall global pooled prevalence of anxiety and depression after correction for publication bias by trim and fill analysis was found to be 24.91(95% CI: 20.8-28.9) for anxiety. The subgroup analyses revealed with the lowest prevalence, 23.59%, (95% CI: 8.08, 39.09)) in North America and the highest, 26.77%, (95% CI: 22.5, 31.04) seen in Europe for anxiety and with the highest prevalence, 18.67%, (95% CI: 9.82, 27.5) in North America and the lowest, 13.27%, (95% CI: -10.05, 16.5) seen in Europe for depression.
The global prevalence of anxiety and depression among cystic fibrosis patients is common. Therefore, close monitoring of the patient, regularly screening for anxiety and depression, and appropriate prevention techniques is recommended.
本系统评价和荟萃分析旨在确定全球囊性纤维化患者的焦虑和抑郁水平。
我们对来自PubMed、EMBASE、MEDLINE、Cochrane、Scopus、Web of Science、CINAHL的已发表研究进行了系统检索，并在谷歌学术上手动检索。本荟萃分析遵循系统评价和荟萃分析的首选报告项目（PRISMA）指南。采用改良的纽卡斯尔-渥太华量表（NOS）评估研究质量。使用STATA™ 14版软件采用随机效应方法进行荟萃分析。采用修剪和填充分析来纠正显著发表偏倚的存在。
从419,820项获得的研究中，来自世界2个不同地区的26项研究，共9766例。经修剪和填充分析校正发表偏倚后，焦虑的全球总体合并患病率为24.91（95%CI：20.8-28.9）。亚组分析显示，焦虑患病率最低的是北美，为23.59%（95%CI：8.08，39.09），最高的是欧洲，为26.77%（95%CI：22.5，31.04）；抑郁患病率最高的是北美，为18.67%（95%CI：9.82，27.5），最低的是欧洲，为13.27%（95%CI：-10.05，16.5）。
囊性纤维化患者中焦虑和抑郁的全球患病率较高。因此，建议密切监测患者，定期筛查焦虑和抑郁，并采取适当的预防措施。
